{"nctId":"NCT00963469","briefTitle":"Montelukast in Seasonal Allergic Rhinitis: Fall 2001 Study (0476-240)","startDateStruct":{"date":"2001-08"},"conditions":["Seasonal Allergic Rhinitis"],"count":1079,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: montelukast sodium"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Comparator: loratadine"]},{"label":"3","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Comparator: placebo"]}],"interventions":[{"name":"montelukast sodium","otherNames":[]},{"name":"Comparator: loratadine","otherNames":[]},{"name":"Comparator: placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient has a history of seasonal allergic rhinitis that worsens during the study season\n* Patient is a nonsmoker\n* Patient is in good health physical and mental health\n\nExclusion Criteria:\n\n* Patient is hospitalized\n* Patient is a woman who is \\< 8 weeks postpartum or is breastfeeding\n* Patient plans to move or vacation away during the study\n* Patient has had any major surgery with in past 4 weeks\n* Patient is a current or past abuser of alcohol or illicit drugs","healthyVolunteers":false,"sex":"ALL","minimumAge":"15 Years","maximumAge":"85 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Change From Baseline in Daytime Nasal Symptoms Score Over First 2 Weeks of Treatment Period","description":"Mean change from baseline in Daytime Nasal Symptoms Score.\n\nPatients were asked to rate each nasal symptom of Congestion, Rhinorrhea, Itching, and Sneezing daily on a 4- point scale \\[Score 0 (best) to 3 (worse)\\]. The average of the 4 individual nasal symptoms scores was reported as the Daytime Nasal Symptoms Score.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.23","spread":null},{"groupId":"OG001","value":"-0.33","spread":null},{"groupId":"OG002","value":"-0.45","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Nighttime Symptoms Score Over First 2 Weeks of Treatment Period","description":"Mean change from baseline in Nighttime Symptoms Score.\n\nPatients were asked to rate each symptom daily on a 4-point scale \\[Score 0 (best) to 3 (worse)\\], and the combined score of Nasal Congestion Upon Awakening, Difficulty Going to Sleep, and Nighttime Awakenings was reported as the Nighttime Symptoms Score.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.18","spread":null},{"groupId":"OG001","value":"-0.28","spread":null},{"groupId":"OG002","value":"-0.25","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Composite Symptoms Score (Daytime Nasal and Nighttime Symptoms) Over First 2 Weeks of Treatment Period","description":"Composite Symptoms Scores were computed as the average of Daytime Nasal Scores \\[Score 0 (best) to 3 (worst)\\] and Nighttime Symptoms Scores \\[Score 0 (best) to 3 (worst)\\].","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.21","spread":null},{"groupId":"OG001","value":"-0.30","spread":null},{"groupId":"OG002","value":"-0.36","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Daytime Eye Symptoms Score Over First 2 Weeks of Treatment Period","description":"Mean change from baseline in Daytime Eye Symptoms scores.\n\nPatients were asked to rate each of the 4 eye symptom of tearing, itchy, red, and puffy eyes daily on a 4-point scale \\[Score 0 (best) to 3 (worst)\\]. The average of the 4 individual eye symptoms scores was reported as the Daytime Eye Symptoms Score.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.18","spread":null},{"groupId":"OG001","value":"-0.28","spread":null},{"groupId":"OG002","value":"-0.33","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient's Global Evaluation of Allergic Rhinitis After First 2 Weeks of Treatment","description":"An evaluation by the patient, administered after the first 2 weeks of treatment using a 7-point scale \\[Score 0 (best) to 6 (worst)\\], of the change in symptoms as compared to the beginning of the study.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.73","spread":null},{"groupId":"OG001","value":"2.43","spread":null},{"groupId":"OG002","value":"2.30","spread":null}]}]}]},{"type":"SECONDARY","title":"Physician's Global Evaluation of Allergic Rhinitis After First 2 Weeks of Treatment","description":"An evaluation by the physician, administered after the first 2 weeks of treatment using a 7-point scale \\[Score 0 (best) to 6 (worst)\\], of the change in symptoms as compared to the beginning of the study.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.75","spread":null},{"groupId":"OG001","value":"2.36","spread":null},{"groupId":"OG002","value":"2.38","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Rhinoconjunctivitis Quality-of-Life Score After First 2 Weeks of Treatment Period","description":"Patients completed a Rhinoconjunctivitis Quality-of-Life Questionnaire-28 questions on a 7-point scale \\[0(best) to 6(worst)\\] across 7 domains: activity,sleep,non-nose/eye symptoms,practical problems,nasal symptoms, eye symptoms, and emotions. The scores for each domain were averaged, then scores for the 7 domains were averaged for an overall score.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.55","spread":null},{"groupId":"OG001","value":"-0.85","spread":null},{"groupId":"OG002","value":"-0.85","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":451},"commonTop":["Headache"]}}}